Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Inc/ US92532F1003 /
VX1/D
|
14/11/2024 16:30:07
|
Var.
-
|
Volume |
Denaro17:30:00 |
Lettera17:30:00 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
|
461.30EUR
|
-
|
66
Fatturato: 26,080.60 |
-Quantità in denaro: - |
-Quantità in lettera: - |
113.92 bill.EUR |
- |
- |
Descrizione business
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
Consiglio di amministrazione & Consiglio di sorveglianza
| CEO |
| Reshma Kewalramani, M.D. |
| Consiglio di amministrazione |
| Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D. |
| Consiglio di sorveglianza |
| Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay |
Dati aziendali
| Name: |
Vertex Pharmaceuticals Inc. |
| Indirizzo: |
50 Northern Avenue,Boston, Massachusetts 02210, USA |
| Telefono: |
+1-617-961-7163 |
| Fax: |
- |
| E-mail: |
Investorinfo@VRTX.com
|
| Internet: |
www.vrtx.com/ |
| Industria: |
Healthcare |
| Settore: |
Pharmaceutical Industry |
| Sub settore: |
Pharmaceuticals |
| Fine dell'anno finanziario: |
31/12 |
| Flottante libero: |
82.70% |
| Data dell'IPO: |
24/07/1991 |
Rapporti con gli investitori
| Name: |
Susie Lisa |
| IR telefono: |
+1-617-341-6108 |
| IR Fax: |
- |
| IR e-mail: |
investorinfo@vrtx.com
|
Principali azionisti
| Altri |
|
53.31% |
| Vanguard Group |
|
8.63% |
| BlackRock Inc. |
|
8.48% |
| Capital World Investors |
|
8.45% |
| FMR LLC. |
|
5.03% |
| State Street Corporation |
|
4.68% |
| ALLIANCEBERNSTEIN L P |
|
2.73% |
| PRICE T ROWE ASSOCIATES INC MD |
|
2.28% |
| GEODE CAPITAL MANAGEMENT LLC |
|
2.20% |
| Altri |
|
4.21% |
